• Something wrong with this record ?

Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase

ED. AlFadly, PA. Elzahhar, A. Tramarin, S. Elkazaz, H. Shaltout, MM. Abu-Serie, J. Janockova, O. Soukup, DA. Ghareeb, AF. El-Yazbi, RW. Rafeh, NZ. Bakkar, F. Kobeissy, I. Iriepa, I. Moraleda, MNS. Saudi, M. Bartolini, ASF. Belal,

. 2019 ; 167 (-) : 161-186. [pub] 20190208

Language English Country France

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19027808

Neuroinflammation and cholinergic deficit are key detrimental processes involved in Alzheimer's disease. Hence, in the search for novel and effective treatment strategies, the multi-target-directed ligand paradigm was applied to the rational design of two series of new hybrids endowed with anti-inflammatory and anticholinesterase activity via triple targeting properties, namely able to simultaneously hit cholinesterases, cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) enzymes. Among the synthesized compounds, triazoles 5b and 5d, and thiosemicarbazide hybrid 6e emerged as promising new hits, being able to effectively inhibit human butyrylcholinesterase (hBChE), COX-2 and 15-LOX enzymes with a higher inhibitory potency than the reference inhibitors tacrine (for hBChE inhibition), celecoxib (for COX-2 inhibition) and both NDGA and Zileuton (for 15-LOX inhibition). In addition, compound 6e proved to be a submicromolar mixed-type inhibitor of human acetylcholinesterase (hAChE). The anti-neuroinflammatory activity of the three most promising hybrids was confirmed in a cell-based assay using PC12 neuron cells, showing decreased expression levels of inflammatory cytokines IL-1β and TNF-α. Importantly, despite the structural resemblance to tacrine, they showed ideal safety profiles on hepatic and murine brain cell lines and were safe up to 100 μM when assayed in PC12 cells. All three hybrids were also predicted to have superior BBB permeability than tacrine in the PAMPA assay, and good physicochemical properties, drug-likeness and ligand efficiency indices. Finally, molecular docking studies highlighted key structural elements impacting selectivity and activity toward the selected target enzymes. To the best of our knowledge, compounds 5b, 5d and 6e are the first balanced, safe and multi-target compounds hitting the disease at the three mentioned hubs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19027808
003      
CZ-PrNML
005      
20190823100849.0
007      
ta
008      
190813s2019 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2019.02.012 $2 doi
035    __
$a (PubMed)30771604
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a AlFadly, Ehab D $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
245    10
$a Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase / $c ED. AlFadly, PA. Elzahhar, A. Tramarin, S. Elkazaz, H. Shaltout, MM. Abu-Serie, J. Janockova, O. Soukup, DA. Ghareeb, AF. El-Yazbi, RW. Rafeh, NZ. Bakkar, F. Kobeissy, I. Iriepa, I. Moraleda, MNS. Saudi, M. Bartolini, ASF. Belal,
520    9_
$a Neuroinflammation and cholinergic deficit are key detrimental processes involved in Alzheimer's disease. Hence, in the search for novel and effective treatment strategies, the multi-target-directed ligand paradigm was applied to the rational design of two series of new hybrids endowed with anti-inflammatory and anticholinesterase activity via triple targeting properties, namely able to simultaneously hit cholinesterases, cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) enzymes. Among the synthesized compounds, triazoles 5b and 5d, and thiosemicarbazide hybrid 6e emerged as promising new hits, being able to effectively inhibit human butyrylcholinesterase (hBChE), COX-2 and 15-LOX enzymes with a higher inhibitory potency than the reference inhibitors tacrine (for hBChE inhibition), celecoxib (for COX-2 inhibition) and both NDGA and Zileuton (for 15-LOX inhibition). In addition, compound 6e proved to be a submicromolar mixed-type inhibitor of human acetylcholinesterase (hAChE). The anti-neuroinflammatory activity of the three most promising hybrids was confirmed in a cell-based assay using PC12 neuron cells, showing decreased expression levels of inflammatory cytokines IL-1β and TNF-α. Importantly, despite the structural resemblance to tacrine, they showed ideal safety profiles on hepatic and murine brain cell lines and were safe up to 100 μM when assayed in PC12 cells. All three hybrids were also predicted to have superior BBB permeability than tacrine in the PAMPA assay, and good physicochemical properties, drug-likeness and ligand efficiency indices. Finally, molecular docking studies highlighted key structural elements impacting selectivity and activity toward the selected target enzymes. To the best of our knowledge, compounds 5b, 5d and 6e are the first balanced, safe and multi-target compounds hitting the disease at the three mentioned hubs.
650    _2
$a acetylcholin $x nedostatek $7 D000109
650    _2
$a Alzheimerova nemoc $x farmakoterapie $x patologie $7 D000544
650    _2
$a zvířata $7 D000818
650    _2
$a buněčné linie $7 D002460
650    _2
$a cholinesterasové inhibitory $x chemie $7 D002800
650    _2
$a inhibitory cyklooxygenasy 2 $x chemie $7 D052246
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x farmakoterapie $7 D007249
650    _2
$a inhibitory lipoxygenas $x chemie $7 D016859
650    _2
$a myši $7 D051379
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a neurony $x účinky léků $x enzymologie $x patologie $7 D009474
650    _2
$a buňky PC12 $7 D016716
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a semikarbazidy $x chemie $x farmakologie $7 D012663
650    _2
$a triazoly $x chemie $x farmakologie $7 D014230
655    _2
$a časopisecké články $7 D016428
700    1_
$a Elzahhar, Perihan A $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
700    1_
$a Tramarin, Anna $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, via Belmeloro 6, 40126, Bologna, Italy.
700    1_
$a Elkazaz, Salwa $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
700    1_
$a Shaltout, Hossam $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; Hypertension & Vascular Research Center, School of Medicine, Wake Forest University, Winston-Salem, NC, 27157, USA.
700    1_
$a Abu-Serie, Marwa M $u City of Scientific Research and Technological Applications (SRTA-City), Egypt.
700    1_
$a Janockova, Jana $u Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Ghareeb, Doaa A $u Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt.
700    1_
$a El-Yazbi, Ahmed F $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; Department of Pharmacology and Toxicology, Faculty of Medicine and Medical Centre, American University of Beirut, Beirut, Lebanon.
700    1_
$a Rafeh, Rim W $u Department of Pharmacology and Toxicology, Faculty of Medicine and Medical Centre, American University of Beirut, Beirut, Lebanon.
700    1_
$a Bakkar, Nour-Mounira Z $u Department of Pharmacology and Toxicology, Faculty of Medicine and Medical Centre, American University of Beirut, Beirut, Lebanon.
700    1_
$a Kobeissy, Firas $u Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Lebanon; Program for Neurotrauma, Neuroproteomics & Biomarkers Research, Department of Emergency Medicine, University of Florida, Gainesville, FL, 32611, USA.
700    1_
$a Iriepa, Isabel $u Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805, Alcalá de Henares, Madrid, Spain; Instituto de Investigación Química Andrés M. del Río (IQAR), Universidad de Alcalá, 28805, Alcalá de Henares, Madrid, Spain.
700    1_
$a Moraleda, Ignacio $u Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805, Alcalá de Henares, Madrid, Spain.
700    1_
$a Saudi, Manal N S $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
700    1_
$a Bartolini, Manuela $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, via Belmeloro 6, 40126, Bologna, Italy. Electronic address: manuela.bartolini3@unibo.it.
700    1_
$a Belal, Ahmed S F $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. Electronic address: ahmed.belal@alexu.edu.eg.
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 167, č. - (2019), s. 161-186
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30771604 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823101103 $b ABA008
999    __
$a ok $b bmc $g 1432957 $s 1066268
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 167 $c - $d 161-186 $e 20190208 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options